Göhring Uwe-Jochen, Eustermann Ira, Becker Martina, Neuhaus Werner, Rein Daniel T, Schöndorf Thomas
Department of Gynecology and Obstetrics, University of Cologne, Germany.
Oncol Rep. 2002 Nov-Dec;9(6):1205-8.
This retrospective study was designed to evaluate the prognostic value of immunohistochemically detected nm23-expression in invasive breast cancer. Cellular expression of nm23 was assessed in 325 primary breast cancer tissues by immunohistochemistry. The data were correlated to established functional factors of prognosis (age, tumor size, nodal status, tumor grade, steroid hormone receptor status), and to clinical follow-up (median observation time, 92 months). 215/325 (66.2%) tumor tissues were considered nm23 positive. nm23 expression did not correlate to any of the investigated markers. Similar results were obtained after subdivision of the patients into node-negative patients (n=153) and node-positive cases (n=172). With respect to clinical outcome, nm23 expression displayed no statistical significance to predict the clinical course. In conclusion, the determination of nm23 expression is an independent factor but lacks prognostic or predictive value in breast cancer patients.
这项回顾性研究旨在评估免疫组化检测的nm23表达在浸润性乳腺癌中的预后价值。通过免疫组化评估了325例原发性乳腺癌组织中nm23的细胞表达情况。将这些数据与已确定的预后功能因素(年龄、肿瘤大小、淋巴结状态、肿瘤分级、类固醇激素受体状态)以及临床随访情况(中位观察时间92个月)进行关联分析。215/325(66.2%)的肿瘤组织被认为nm23呈阳性。nm23表达与任何一项所研究的标志物均无相关性。将患者分为淋巴结阴性患者(n = 153)和淋巴结阳性患者(n = 172)后,也得到了类似结果。就临床结局而言,nm23表达对预测临床病程无统计学意义。总之,nm23表达的测定是一个独立因素,但在乳腺癌患者中缺乏预后或预测价值。